| Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 18781825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In spite of its rather specific name, glycogen synthase kinase-3 (GSK-3) is an eclectic cellular regulator that modulates an array of processes from nuclear transcription, to neurological functions and metabolism. The enzyme is also a focal point for diverse signaling pathways that act to suppress its activity. OBJECTIVES: To review recent evidence supporting the important role GSK-3 plays in glucose homeostasis and discuss the therapeutic potential of inhibiting this enzyme in the treatment of diabetes and insulin resistance. RESULTS/CONCLUSION: Despite its pleiotropic nature, GSK-3 has significant promise as a target for diabetes due to functional partitioning of the enzyme, tissue-selectivity and acute dosage-dependency of effects of inhibition, suggesting useful therapeutic windows. |
| | |
Authors:
|
Katrina MacAulay; James R Woodgett |
Related Documents
:
|
18393105 - Advances in glycogen phosphorylase inhibitor design. 16140165 - Tramadol enhances hepatic insulin sensitivity via enhancing insulin signaling cascade i... 10218965 - Ro 31-8220 activates c-jun n-terminal kinase and glycogen synthase in rat adipocytes an... 6817965 - 5-hydroxytryptamine, glucose uptake, glycogen utilization and carbon dioxide fixation i... 19177815 - Glycemic control in diabetic and non-diabetic cardiac surgical patients and length of h... 19668445 - Cystoid macular edema. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert opinion on therapeutic targets Volume: 12 ISSN: 1744-7631 ISO Abbreviation: Expert Opin. Ther. Targets Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-10 Completed Date: 2008-12-29 Revised Date: 2010-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 101127833 Medline TA: Expert Opin Ther Targets Country: England |
Other Details:
|
Languages: eng Pagination: 1265-74 Citation Subset: IM |
Affiliation:
|
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
drug therapy* Enzyme Inhibitors / therapeutic use* Glycogen Synthase Kinase 3 / antagonists & inhibitors*, metabolism Humans Insulin / physiology Insulin Resistance Signal Transduction Substrate Specificity |
| Grant Support | |
ID/Acronym/Agency:
|
12043//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 11061-68-0/Insulin; EC 2.7.11.26/Glycogen Synthase Kinase 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibiting angiotensin type 1 receptors as a target for diabetes.
Next Document: Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target.